{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:36:59Z","timestamp":1770356219400,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NIH\/NCI","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}]},{"name":"NIH\/NCI","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s10549-022-06658-5","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T13:02:45Z","timestamp":1656766965000},"page":"507-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer"],"prefix":"10.1007","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5525-3748","authenticated-orcid":false,"given":"Kristine","family":"Doney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-0906","authenticated-orcid":false,"given":"Wendy","family":"Leisenring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5048-2819","authenticated-orcid":false,"given":"Hannah","family":"Linden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"issue":"6","key":"6658_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69(6):438\u2013451","journal-title":"CA Cancer J Clin"},{"key":"6658_CR2","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER Cancer Statistics Review, 1975\u20132017. In.: National Cancer Institute, Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2017\/, based on November 2019 SEER data submission, posted to the SEER web site, April\u00a02020."},{"issue":"5","key":"6658_CR3","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/1097-0142(19900901)66:5<874::AID-CNCR2820660511>3.0.CO;2-6","volume":"66","author":"RS Lavey","year":"1990","unstructured":"Lavey RS, Eby NL, Prosnitz LR (1990) Impact of radiation therapy and\/or chemotherapy on the risk for a second malignancy after breast cancer. Cancer 66(5):874\u2013881","journal-title":"Cancer"},{"issue":"26","key":"6658_CR4","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJM199206253262605","volume":"326","author":"RE Curtis","year":"1992","unstructured":"Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN (1992) Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326(26):1745\u20131751","journal-title":"N Engl J Med"},{"issue":"12","key":"6658_CR5","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1200\/JCO.2000.18.12.2406","volume":"18","author":"E Obedian","year":"2000","unstructured":"Obedian E, Fischer DB, Haffty BG (2000) Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 18(12):2406\u20132412","journal-title":"J Clin Oncol"},{"issue":"1","key":"6658_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1054\/bjoc.2000.1196","volume":"83","author":"R Saso","year":"2000","unstructured":"Saso R, Kulkarni S, Mitchell P, Treleaven J, Swansbury GJ, Mehta J, Powles R, Ashley S, Kuan A, Powles T (2000) Secondary myelodysplastic syndrome\/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 83(1):91\u201394","journal-title":"Br J Cancer"},{"issue":"7","key":"6658_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1200\/JCO.2003.03.114","volume":"21","author":"RE Smith","year":"2003","unstructured":"Smith RE, Bryant J, DeCillis A, Anderson S (2003) National Surgical Adjuvant B, Bowel Project E: Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21(7):1195\u20131204","journal-title":"J Clin Oncol"},{"issue":"18","key":"6658_CR8","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1200\/JCO.2005.05.029","volume":"23","author":"C Praga","year":"2005","unstructured":"Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R et al (2005) Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23(18):4179\u20134191","journal-title":"J Clin Oncol"},{"issue":"25","key":"6658_CR9","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1200\/JCO.2007.12.0832","volume":"25","author":"DA Patt","year":"2007","unstructured":"Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH (2007) Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 25(25):3871\u20133876","journal-title":"J Clin Oncol"},{"issue":"5","key":"6658_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/sj.bjc.6604241","volume":"98","author":"YM Kirova","year":"2008","unstructured":"Kirova YM, De Rycke Y, Gambotti L, Pierga JY, Asselain B, Fourquet A (2008) Institut curie breast cancer study G: second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 98(5):870\u2013874","journal-title":"Br J Cancer"},{"issue":"2","key":"6658_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ijrobp.2006.12.011","volume":"68","author":"YM Kirova","year":"2007","unstructured":"Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A (2007) Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys 68(2):359\u2013363","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6658_CR12","doi-asserted-by":"crossref","unstructured":"Karp JEBA, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, et al (2012) Myelodysplastic syndrome and\/or acute myelogenous leukemia (MDS and\/or AML) after a breast cancer diagnosis: the National Comprehensive Cancer Network (NCCN) experience. In:\u00a0Paper presented at the\u00a0American Association of Cancer Research. https:\/\/cancerres.aacrjournals.org\/content\/72\/24_Supplement\/S3-5","DOI":"10.1158\/0008-5472.SABCS12-S3-5"},{"key":"6658_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.breast.2017.07.004","volume":"35","author":"LM Burt","year":"2017","unstructured":"Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK (2017) Risk of secondary malignancies after radiation therapy for breast cancer: comprehensive results. Breast 35:122\u2013129","journal-title":"Breast"},{"issue":"1","key":"6658_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canrad.2016.07.101","volume":"21","author":"L Bazire","year":"2017","unstructured":"Bazire L, De Rycke Y, Asselain B, Fourquet A, Kirova YM (2017) Risks of second malignancies after breast cancer treatment: long-term results. Cancer Radiother 21(1):10\u201315","journal-title":"Cancer Radiother"},{"key":"6658_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.14694\/EdBook_AM.2013.33.9","volume":"2013","author":"EL Mayer","year":"2013","unstructured":"Mayer EL (2013) Early and late long-term effects of adjuvant chemotherapy. Am Soc Clin Oncol 2013:9\u201314","journal-title":"Am Soc Clin Oncol"},{"issue":"9","key":"6658_CR16","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1097\/TP.0b013e3181a238f6","volume":"87","author":"Y Miao","year":"2009","unstructured":"Miao Y, Everly JJ, Gross TG, Tevar AD, First MR, Alloway RR, Woodle ES (2009) De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 87(9):1347\u20131359","journal-title":"Transplantation"},{"issue":"4","key":"6658_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2307\/2530374","volume":"34","author":"RL Prentice","year":"1978","unstructured":"Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE (1978) The analysis of failure times in the presence of competing risks. Biometrics 34(4):541\u2013554","journal-title":"Biometrics"},{"issue":"5","key":"6658_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hernan MA, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11(5):550\u2013560","journal-title":"Epidemiology"},{"issue":"19","key":"6658_CR19","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M et al (2017) 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836\u20131846","journal-title":"N Engl J Med"},{"issue":"4","key":"6658_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447","journal-title":"Blood"},{"issue":"12","key":"6658_CR21","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 15(12):1628\u20131633","journal-title":"Biol Blood Marrow Transplant"},{"key":"6658_CR22","unstructured":"Why, When and Where to Report Conditioning Drugs [https:\/\/www.cibmtr.org\/Meetings\/Materials\/CRPDMC\/Pages\/2015Index.aspx ]. Accessed 11 Feb 2021"},{"issue":"2","key":"6658_CR23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.trre.2013.12.002","volume":"28","author":"M AlBugami","year":"2014","unstructured":"AlBugami M, Kiberd B (2014) Malignancies: pre and post transplantation strategies. Transplant Rev (Orlando) 28(2):76\u201383","journal-title":"Transplant Rev (Orlando)"},{"issue":"1","key":"6658_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.suc.2018.09.004","volume":"99","author":"AP Rossi","year":"2019","unstructured":"Rossi AP, Klein CL (2019) Posttransplant Malignancy. Surg Clin North Am 99(1):49\u201364","journal-title":"Surg Clin North Am"},{"issue":"4","key":"6658_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.trre.2012.07.001","volume":"26","author":"JM Campistol","year":"2012","unstructured":"Campistol JM, Cuervas-Mons V, Manito N, Almenar L, Arias M, Casafont F, Del Castillo D, Crespo-Leiro MG, Delgado JF, Herrero JI et al (2012) New concepts and best practices for management of pre- and post-transplantation cancer. Transplant Rev (Orlando) 26(4):261\u2013279","journal-title":"Transplant Rev (Orlando)"},{"issue":"9","key":"6658_CR26","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1111\/ajt.14368","volume":"17","author":"G Wong","year":"2017","unstructured":"Wong G, Au E, Badve SV, Lim WH (2017) Breast cancer and transplantation. Am J Transplant 17(9):2243\u20132253","journal-title":"Am J Transplant"},{"issue":"9","key":"6658_CR27","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1111\/j.1600-6143.2007.01908.x","volume":"7","author":"AC Webster","year":"2007","unstructured":"Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR (2007) Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 7(9):2140\u20132151","journal-title":"Am J Transplant"},{"issue":"23","key":"6658_CR28","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","volume":"296","author":"CM Vajdic","year":"2006","unstructured":"Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE (2006) Cancer incidence before and after kidney transplantation. JAMA 296(23):2823\u20132831","journal-title":"JAMA"},{"key":"6658_CR29","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised","author":"SCE Swerdlow","year":"2017","unstructured":"Swerdlow SCE, Harris NL et al (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised, 4th edn. International Agency for Research on Cancer IARC, Lyon","edition":"4"},{"issue":"2","key":"6658_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4081\/oncol.2019.425","volume":"13","author":"G Lazarus","year":"2019","unstructured":"Lazarus G, Audrey J, Iskandar AWB (2019) Efficacy and safety profiles of programmed cell death-1\/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review. Oncol Rev 13(2):425","journal-title":"Oncol Rev"},{"key":"6658_CR31","doi-asserted-by":"publisher","first-page":"575978","DOI":"10.3389\/fonc.2020.575978","volume":"10","author":"A Bertucci","year":"2020","unstructured":"Bertucci A, Bertucci F, Zemmour C, Lerebours F, Pierga JY, Levy C, Dalenc F, Grenier J, Petit T, Berline M et al (2020) PELICAN-IPC 2015\u2013016\/Oncodistinct-003: a prospective, multicenter, open-label, randomized, non-comparative, phase ii study of pembrolizumab in combination with neo adjuvant EC-paclitaxel regimen in HER2-negative inflammatory breast cancer. Front Oncol 10:575978","journal-title":"Front Oncol"},{"issue":"9","key":"6658_CR32","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810\u2013821","journal-title":"N Engl J Med"},{"issue":"22","key":"6658_CR33","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1200\/JCO.20.02923","volume":"39","author":"AS Alva","year":"2021","unstructured":"Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P et al (2021) Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol 39(22):2443\u20132451","journal-title":"J Clin Oncol"},{"issue":"1","key":"6658_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, Tariq MJ, Durer S, Durer C, Russ A et al (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 25(1):94\u201399","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"6658_CR35","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1182\/blood-2017-10-752154","volume":"131","author":"RJ Soiffer","year":"2018","unstructured":"Soiffer RJ, Davids MS, Chen YB (2018) Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Blood 131(10):1073\u20131080","journal-title":"Blood"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06658-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06658-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06658-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T04:25:39Z","timestamp":1657859139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06658-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["6658"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06658-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"29 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not disclosed any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}